Future of Cancer Immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium History and Evolution of Immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Modern era of cancer immunotherapy began in 1994-1996, CTLA-4 controls T cell function and anti-tumor immunity
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium CTLA-4 blockade in metastatic melanoma - Ipilimumab
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium The Checkpoint Inhibitor, PD-1, amplifies and transforms the field
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Combining PD-1 and CTLA-4 blockade in metastatic melanoma
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium A second key discovery, cell therapy - a complementary effort to target tumors with limited immunogenicity
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 8
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Chimeric Antigen Receptor: CD19CAR T-cell that changed to field
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Major CAR-T Milestones: First Approvals in 2017
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Immunotherapy delivers - 10 FDA immunotherapy approval milestones in 6 years
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium We have made enormous progress with approved drugs, first-in-class treatments and novel treatments.
But none of them are fully curative and many tumors can’t be treated.
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 14
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium And…that’s actually what’s happening in the clinic
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 16
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Better Biomarkers will be able to predict efficacy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Planned Studies: Biomarker Driven
Fix the agents and change biomarkers
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium IO Master Platform Protocol: PD1
Resistance
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 21
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 22
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Response rate not fully correlated with mutational load
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 24
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 25
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI Pancreatic Cancer Clinical Trial
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 28
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Differences in gut microbiome:
anti-PD-1 responders v. non-responders
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI0014: Evaluate safety, tolerability and efficacy of microbiome therapy in metastatic melanoma
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen immunotherapy
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI T Cell Engineering Initiative
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium New possibilities for cell engineering
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium NY-ESO-1 engineered TCR & PD-1 knockout
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium New approaches in CAR-T
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 36
Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium